The FDA granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics) for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma, after two or more lines of systemic therapy.
“There is a significant unmet need for treatment options for patients with R/R DLBCL, including those who have been heavily